RAS genes are the most frequently mutated oncogenes in cancer. These mutations occur in
roughly half of the patients with colorectal cancer (CRC). RAS mutant tumors are resistant to …

Colorectal cancer (CRC) is among the most common cancers. In fact, it is placed in the third
place among the most diagnosed cancer in men, after lung and prostate cancer, and in the …

Purpose: We evaluated the influence of RAS mutation status on the treatment effect of
panitumumab in a prospective–retrospective analysis of a randomized, multicenter phase III …

NRAS mutations occur in 3–5% of colorectal cancer. Differently from KRAS and BRAF
mutations, the role of NRAS mutations as prognostic and predictive markers in metastatic …

Various translocations and mutations have been identified in myeloma, and certain
aberrations, such as t (4; 14) and del17, are linked with disease prognosis. To investigate …

Human oncoproteins promote transformation of cells into tumours by dysregulating the
signalling pathways that are involved in cell growth, proliferation and death. Although …

Ras GTPases are mutated at codons 12, 13, and 61, with different frequencies in KRas,
HRas, and NRas and in a cancer-specific manner. The G13D mutant appears in 25% of …

Purpose: NRAS mutations are now routinely included in RAS testing prior to EGFR inhibitor
therapy for metastatic colorectal cancer (mCRC). The clinical implications of NRAS mutation …

Somatic mutation status in metastatic colorectal cancer (mCRC) is becoming increasingly
clinically relevant as it may be correlated not only with response to biologic therapies, but …

This study aimed to estimate the incidence of KRAS, NRAS, and BRAF mutations in the
Moroccan population, and investigate the associations of KRAS and NRAS gene mutations …